TearClear Appoints Robert Bailey to Board of Directors
Bailey’s executive experience in the Ophthalmology industry further strengthens the organization.
DetailsBailey’s executive experience in the Ophthalmology industry further strengthens the organization.
DetailsElad Kedar discuss the Presbyopia Market and the closing of the recent Series C round with Endpoints News.
DetailsOrasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the closing of a $30 million Series C financing. The financing was co-led by new investor Bluestem Capital and returning investor Visionary Ventures, with participation from other returning investors Sequoia Capital, SBI (Japan) Innovation Fund, Maverick Ventures, LifeSci Venture Partners and additional investors.
DetailsTearClear Raises $22 Million from Visionary Ventures, Bluestem Capital, Flying L Partners, and KKR to Advance Multiple Clinical Programs in Development. In addition to the financing, TearClear also announces the appointment of the former Chief Executive Officer of Galderma, Stuart Raetzman, to Board of Directors.
DetailsRe-Vana ranks 10th in BusinessCloud’s Northern Ireland Tech 50 ranking for 2020.
DetailsTarsus TP-03: Potential Game-Changer for Demodex Blepharitis
DetailsSesha Neervannan, PhD, to assume position of Chief Operating Officer; Leo Greenstein to assume position of Chief Financial Officer
DetailsRobert J. Dempsey recently joined TearClear, an emerging global ophthalmic pharmaceutical company with a focus on eye drops that are preserved safely prior to administering dosing, as Chief Executive Officer. Prior to this role, Mr. Dempsey held positions at Shire (Takeda, now Novartis), Bausch + Lomb, Allergan and Inspire Pharmaceuticals. What follows is a Q&A with Mr. Dempsey, where he reveals, among other things, his love of American history.
DetailsRe-Vana Completes $3.25MM Pre-Series A Financing led by Visionary Ventures and ExSight Ventures to Support Pre-clinical Development of Sustained Release Biologic and Small Molecule Therapeutics.
DetailsTarsus Presents Positive Results of the Jupiter Study, a Phase 2b Randomized Controlled Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Blepharitis Due to Demodex Infestation, at AOA 2020 Virtual Meeting
Details